8-K: Medifast Q3 Revenue Plunges 36%, Reports Net Loss

Medifast reported a significant 36.2% revenue decrease to $89.4 million and a net loss of $2.3 million in Q3 2025, primarily due to declining active coaches and GLP-1 medication impact.

Summary

• Revenue for the third quarter of 2025 decreased 36.2% to $89.4 million, down from $140.2 million in Q3 2024.
• The company reported a net loss of $2.3 million, or $0.21 loss per diluted share, compared to net income of $1.1 million, or $0.10 per diluted share, in Q3 2024.
• The number of independent active earning OPTAVIA coaches decreased 35.0% to 19,500, down from 30,000 in Q3 2024.
• Average revenue per active earning OPTAVIA coach was $4,585, a decrease from $4,672 in Q3 2024.
• Gross profit decreased 41.2% to $62.2 million, with gross profit margin falling to 69.5% from 75.4% in Q3 2024.
• Loss from operations was $4.1 million, compared to income from operations of $2.1 million in the prior-year period.
• Selling, general, and administrative expenses (SG&A) decreased 36.0% to $66.2 million, primarily due to lower coach compensation and reduced marketing and convention costs.
• The balance sheet remains strong with $173.5 million in cash, cash equivalents, and investment securities and no debt as of September 30, 2025.
• Management is transforming Medifast from a weight-loss company into a leader in promoting metabolic health, positioning itself in a larger, more durable market.

Sentiment

Score: 3

Explanation: The company faces severe financial deterioration with substantial year-over-year declines in revenue, active coaches, and a shift from profit to significant losses. The competitive landscape, particularly the rise of GLP-1 medications, poses an existential threat to its traditional business model. While management is attempting a strategic pivot, the immediate financial results and outlook are negative. The strong balance sheet provides some stability, but the core business is under severe pressure.

Positives

• Maintained a strong balance sheet with $173.5 million in cash, cash equivalents, and investment securities and no debt as of September 30, 2025.
• Strategic evolution to focus on metabolic health aims to position the company in a larger, more durable market with strong consumer tailwinds.
• Other income increased by approximately $2.0 million due to the absence of a loss on the company's investment in LifeMD, Inc. common stock that occurred in the prior year.
• Selling, general, and administrative expenses decreased by $37.4 million (36.0%) year-over-year, driven by lower coach compensation, reduced company-led marketing, and non-recurring convention and LifeMD collaboration costs.

Negatives

• Revenue decreased significantly by 36.2% to $89.4 million in Q3 2025 compared to Q3 2024.
• Reported a net loss of $2.3 million, or $0.21 loss per diluted share, a reversal from net income of $1.1 million in Q3 2024.
• The total number of active earning OPTAVIA coaches decreased 35.0% to 19,500, continuing a downward trend since Q1 2023.
• Client acquisition challenges persist due to the growing acceptance and rapid adoption of GLP-1 medications for weight loss.
• Gross profit decreased 41.2% to $62.2 million, and gross profit margin declined to 69.5% from 75.4% in Q3 2024, impacted by loss of leverage on fixed costs and product reformulation reserves.
• Experienced a loss from operations of $4.1 million, compared to income from operations of $2.1 million in the prior-year period.
• SG&A as a percentage of revenue increased to 74.1% from 73.9% year-over-year, primarily due to loss of leverage on fixed costs.
• Fourth quarter 2025 revenue is projected to be lower, in the range of $65 million to $80 million, and diluted loss per share is expected to widen to $0.70 to $1.25.

Risks

• Inability to maintain and grow the network of independent OPTAVIA coaches.
• Industry competition and new weight loss products, including weight loss medications (GLP-1s), or services.
• Health or advertising related claims by OPTAVIA clients.
• Inability to continue to develop new products.
• Effectiveness of advertising and marketing programs, including use of social media by OPTAVIA coaches.
• The departure of one or more key personnel.
• Inability to protect against online security risks and cyberattacks.
• Risks associated with the direct-to-consumer business model.
• Disruptions in the supply chain.
• Product liability claims.
• Challenges with planned growth into domestic markets and transformation to promote metabolic health.
• Adverse publicity associated with products.
• The impact of existing and future laws and regulations on the business.
• Fluctuations of common stock market price.
• Increases in litigation.
• Actions of activist investors.
• The consequences of other geopolitical events, overall economic and market conditions and the resulting impact on consumer sentiment and spending patterns.
• Inability to prevent or detect a failure of internal control over financial reporting.

Future Outlook

Medifast expects fourth quarter 2025 revenue to be in the range of $65 million to $80 million and fourth quarter 2025 diluted loss per share to be in the range of $0.70 to $1.25.

Management Comments

• "We're transforming Medifast from a weight-loss company into a leader in promoting metabolic health."
• "Our clinically proven, coach-guided system does more than help people lose weight—it addresses the underlying metabolic dysfunction that drives most health challenges."
• "This strategic evolution positions us in a larger, more durable market with strong consumer tailwinds. It's a transformation founded in proven science that creates meaningful health outcomes."
• "With a strong balance sheet, a passionate coach community, and clinically proven plans, we believe Medifast is well positioned to become the trusted partner for millions seeking metabolic health."

Industry Context

Medifast is facing significant industry headwinds, primarily from the rapid adoption and growing acceptance of GLP-1 medications for weight loss, which are directly impacting its client acquisition and traditional weight-loss business model. In response, the company is strategically pivoting to rebrand itself as a leader in 'metabolic health' to address underlying metabolic dysfunction, aiming to position itself in a larger and more durable market beyond conventional weight loss.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct assessment against global benchmarks.

Stakeholder Impact

• Shareholders are likely to experience negative impact due to significant revenue decline, net loss, and a negative outlook, which could lead to downward pressure on the share price.
• Employees and coaches may be impacted by decreased coach compensation resulting from fewer active earning coaches and lower sales volumes, potentially affecting retention and morale.
• Customers may see a shift in product offerings and focus as the company pivots its strategy towards metabolic health from traditional weight loss.

Next Steps

• Continue the strategic evolution to transform into a leader in promoting metabolic health.
• Host a conference call on November 3, 2025, to discuss the third quarter results.
• Work towards achieving fourth quarter 2025 revenue in the range of $65 million to $80 million and diluted loss per share in the range of $0.70 to $1.25.

Key Dates

Recommendation

The company is experiencing severe financial deterioration with substantial year-over-year declines in revenue, active coaches, and a shift from profit to significant losses. The competitive landscape, particularly the rise of GLP-1 medications, poses an existential threat to its traditional business model. While a strategic pivot to metabolic health is underway, its success is uncertain and the immediate outlook remains highly negative, projecting further revenue contraction and increased losses. The strong balance sheet offers some liquidity but does not mitigate the fundamental business challenges. Investors should consider selling given the significant headwinds and uncertain turnaround prospects.

Keywords

Medifast, MED, OPTAVIA, Q3 2025 earnings, financial results, metabolic health, weight loss, GLP-1 medications, direct selling, health and wellness, coach-guided system, financial performance, revenue, net loss, active coaches